

THE WHO CEWG PROCESS AS UNIQUE OPPORTUNITY TO IMPLEMENT ALTERNATIVE R&D MODELS

Drugs for Neglected Disease *initiative*- DNDi

UAEM

The Hague- February 5 2016

OPPORTUNITY

- To Structurally & multilaterally address twofold problem:
 - Lack of innovation for non profitable markets (Ebola, Malaria, Zika)
 - High prices barring access to existing treatments

BACKGROUND

- *'Intellectual property protection is not relevant for diseases where there is no profitable market'* CIPIH – 2003
- This was over 10 years ago. Now, we know that *the current medical R&D system as a whole is not sustainable.*

OVER 10-YEAR DISCUSSION AT WHA LEVEL TO FIND A SUSTAINABLE SOLUTION



April 2016 WHO Open-ended meeting

CEWG RECOMMENDATIONS

- Negotiate Global Agreement on R&D
- 3 principles:
 - Open knowledge innovation
 - Equitable access licencing
 - De-linkage

2013 RESOLUTION

Governments agree to experiment:

- **Demonstration projects,**
- **Set up a global R&D observatory,**
- **Explore set up of pooled fund**


Postpone to 2016: **Global Agreement**

THE GLOBAL BIOMEDICAL R&D FUND AND MECHANISM

Funding for R&D initiatives



...and others



WHAT'S HAPPENING NOW?

- Solutions & principles are there. nb
- Political will lacking

- Open Ended Meeting April
- WHA 2016

WHAT SHOULD HAPPEN?

- Coordination between initiatives needed vs fragmentation
 - Overarching agreement
 - Broad Scope
 - Apply key principles to anything going forward
- We need to scale up!

Academic Sign-on letter

Joseph E. Stiglitz, Nobel Laureate, Member of the National Academy of Science, Corresponding Fellow, Royal Society.

Sir John Sulston, Nobel Laureate, Fellow of the Royal Society

Warren Kaplan, PhD, JD, MPH: Center for **Global Health & Development/Boston** University School of Public Health

Amy Kapczynski, JD, MA, MPhil, AB: **Professor of Law; Faculty Director Global Health Justice** Partnership, Yale Law School

Benjamin Coriat, Professeur des Universités **Faculté des Sciences Economiques**. Université Paris 13. Sorbonne Paris Cité, France

Dean Baker, Co-Director, **Center for Economic and Policy Research**



Make Medicines for People Not for Profit

Towards an Agreement on Biomedical Research and Development for the Public Benefit: Academia's Urgent Call to Action[Leer en español](#)[Lire en français](#)As members of the international academic and scientific community, we call upon the member states of the World Health Organisation (WHO) to negotiate a much overdue global research and development (R&D) agreement to ensure innovation and access to affordable vaccines, medicines and life-saving technologies for all.

In an open letter in 2008, leading academics, researchers and scientists, including many of us, urged universities and research institutes to set policies for research and technology transfer that serve the public good, while calling on the WHO's Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property to find new mechanisms to address a failing system of R&D on medicine and health technologies.

In 2012, the WHO's Consultative Expert Working Group on Research and Development: Financing

- Why: The need to change our RnD system
- How: Unite academics and researchers
- What: To push for political change
- Where: Globally
- When: 2016

Where do we stand now?

UNAEM

UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES

